Notice of Q2 conference call and webcast

    Notification of conference call and webcast

Cambridge, UK and Cambridge, Massachusetts - 3 September 2003 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) will announce its second quarter results
for the period ended 30 June 2003 on Tuesday, 16 September 2003.

The results announcement will be released at 7.00 am BST. A meeting and
conference call for analysts will be held at 9.30 am BST at the offices of
Deutsche Bank, Winchester House, 1 Great Winchester Street, London EC2. For
details, contact Mo Noonan at Financial Dynamics on telephone number +44 (0) 20
7269 7116. An instant replay of the conference call will be available until
midnight on Tuesday, 23 September on the following telephone numbers: UK: +44
(0) 20 8288 4459; US: [phone]. The pin code is 601842.

An audio webcast of the call will also be available via Acambis' website at
www.acambis.com. The webcast replay will be available until midnight on
Thursday, 16 October.

                                    -ends-                                     

Enquiries:

Acambis plc                                                                    
                                                                               
Lyndsay Wright, Director of              Tel: [phone]             
Communications                                                                 
                                                                               
Financial Dynamics                                                             
                                                                               
Mo Noonan                                Tel: [phone]             

Notes to editors:

Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis provides governments around the world with the full portfolio
of related smallpox vaccine products required to protect their citizens against
the threat of smallpox virus being used as a bioterrorist weapon. Acambis is
establishing a travel vaccines franchise, including vaccines against yellow
fever, Japanese encephalitis, dengue fever and typhoid. Acambis also has the
most advanced vaccine in development targeting the West Nile virus, which has
spread to over 40 US States in the last three years.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on Nasdaq (ACAM). More information is
available at www.acambis.com.



END